<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The T-type calcium channel inhibitor Mibefradil was reported to protect the heart from atrial remodeling, a key process involved in the development of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Mibefradil is not a selective T-type calcium channel inhibitor and also affects the function of different ion channels </plain></SENT>
<SENT sid="2" pm="."><plain>Our aim was to develop a selective T-type calcium channel inhibitor to validate the importance of T-type-related pharmacology in <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Structural optimisation of a previously disclosed hit series focussed on minimising exposure to the central <z:mp ids='MP_0008912'>nervous</z:mp> system and improving pharmacokinetic properties, while maintain adequate potency and selectivity </plain></SENT>
<SENT sid="4" pm="."><plain>This resulted in the design of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(<z:chebi fb="0" ids="24712">hydroxymethyl</z:chebi>)-4-piperidyl]<z:chebi fb="36" ids="29309">methyl</z:chebi>]-3,5-dichloro-<z:chebi fb="0" ids="28179">benzamide</z:chebi>, a novel, selective, peripherally restricted chemical probe to verify the role of T-type calcium channel inhibition on <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> protection </plain></SENT>
</text></document>